Clovertex’s January Target of the Month is Dopamine D2 Receptor (D2R), highlighted by Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies, announced at the J.P. Morgan Healthcare Conference. D2R is a key receptor in the dopamine signaling pathway, playing a central role in schizophrenia, bipolar disorder, and other psychiatric conditions.
The deal centers on lumateperone (Caplyta®), a next-generation antipsychotic that modulates D2R activity while also affecting serotonin pathways, offering a differentiated approach to treating severe mental illnesses. With this acquisition, J&J strengthens its position in neuroscience, reflecting the growing commercial interest in innovative psychiatric treatments. More importantly, it underscores the urgent need for better therapies in a space where millions still struggle with debilitating conditions including depression.
The Protein Imager rendering displays the cryo-EM structure of native dystrophin-glycoprotein complex (PDB entry 8IRS).
Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.
1. J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders
2. Clovertex website